Novartis' key multiple sclerosis product Gilenya gets approval in China
Novartis is reimagining medicine to improve and extend people's lives. As a leading global medicines company, it use innovative science and digital technologies to create transformative treatments in areas of great medical need.
Multiple sclerosis (MS) is categorized as rare disease in China with an estimated 30,000 MS patients in China. Gilenya is the 3rd most prescribed MS disease modifying treatment worldwide. Today, Gilenya is widely recognized by doctors with over 283,000 patients treated with Gilenya to date.
Novartis is committed to bringing innovation to China and to reimagining care for patients. Entresto® was approved in 2017. Following the approval of Cosentyx® in March, Gilenya is the next key Novartis product approved from the list of urgently needed drugs in China.